Virax Biolabs Group (NASDAQ: VRAX) is a biotechnology company focused on the development and GMP-compliant manufacturing of next-generation vaccines and immunotherapies. Headquartered in Melbourne, Australia, the company operates a purpose-built, fully certified biologics facility capable of producing clinical- and commercial-scale batches of viral vectors, protein subunit vaccines and oncolytic viruses. In addition to its in-house pipeline, Virax offers contract development and manufacturing services (CDMO) to pharmaceutical and biotech partners worldwide, leveraging its quality-driven infrastructure to support programs from preclinical stages through late-stage clinical trials.
The company’s proprietary pipeline targets both infectious diseases and cancer. Lead programs include novel vaccine candidates for herpes simplex virus and seasonal influenza, as well as oncolytic viral therapies designed to stimulate anti-tumor immune responses. Virax’s vaccine platform draws on licensed RNA and DNA vaccine technologies, while its cancer immunotherapy efforts harness engineered viral vectors to deliver tumor-specific antigens. By integrating research, process development and manufacturing capabilities under one roof, Virax aims to accelerate timelines and de-risk the transition from laboratory discovery to human studies.
Founded by a team of vaccine scientists and bioprocess engineers, Virax Biolabs has expanded its footprint through strategic collaborations and technology licensing agreements. The group maintains research partnerships with leading academic institutions in the United States and Europe and has engaged with government agencies on pandemic preparedness programs. Its Melbourne facility adheres to stringent International Council for Harmonisation (ICH) and World Health Organization (WHO) guidelines, enabling global supply support for both proprietary and third-party products.
Leadership at Virax combines decades of experience in the biopharmaceutical sector. Chief Executive Officer Michael Young previously held senior roles at major vaccine and plasma companies, while Chief Scientific Officer Dr. Clara Reynolds brings expertise in viral vector design and immunology. Together with Chief Operating Officer Angela Wang—who oversaw multiple GMP facility launches—the executive team focuses on driving pipeline advancement, expanding contract manufacturing operations and forging new alliances to address unmet medical needs across North America, Europe and Asia.
AI Generated. May Contain Errors.
Free VRAX Stock Alerts